Sign up for alerts
Want to make sure you never miss the latest updates?
Insights with impact
Industry Insight
The biology of roginolisib: Activity without immune toxicity
Industry Insight
End of year reflections from our CEO
Industry Insight
Driving breakthroughs for myelofibrosis care
Industry Insight
What’s next for cambritaxestat?
Industry Insight
Realizing the potential of PI3Kδ inhibitors in peripheral T-cell lymphomas
Industry Insight
iOnctura expands roginolisib trials to the US
Industry Insight
iOnctura enhances board to accelerate growth and innovation
Industry Insight
Addressing drug resistance in non-small cell lung cancer
Industry Insight
Scientific innovation in uveal melanoma
Industry Insight
Opportunities and challenges in oncology immunotherapy
Industry Insight
Reflections from our CEO
Industry Insight
Pancreatic cancer – our commitment to scientific advances
Industry Insight
A bold new era in global cancer drug discovery
Industry Insight
A note from our CEO
Industry Insight
Realising the potential of autotaxin therapy in cancer
Industry Insight
PI3Kδ inhibitors offer serious promise in solid tumors
Industry Insight
Emerging therapies offer hope for uveal melanoma patients
All news
Press release
A promising new chapter for PI3Kδ inhibition: Nature Communications publications reveal novel mechanism behind iOnctura’s roginolisib
Data & publication
Roginolisib in Combination with JAK Inhibitors in Patients with Myelofibrosis Who are Unresponsive to Approved JAK Inhibitors (Study HEMA-MED) – A Trial in Progress
Data & publication
The conformation-selective PI3Kδ inhibitor roginolisib synergizes with JAK inhibitors in progenitor cells from naïve and JAK inhibitor-refractory/resistant patients with myelofibrosis
Data & publication
Proteomic evidence of on-target activity of cambritaxestat (IOA-289) in patients with metastatic pancreatic ductal adenocarcinoma
Data & publication
Patient tumor profiling supports the antitumor activity of the autotaxin inhibitor cambritaxestat (IOA‑289) as monotherapy and in combination with standard of care in hepatocellular carcinoma and cholangiocarcinoma
Data & publication
From the gene to the clinic: Key milestones in the PI3Kδ journey
Data & publication
Contemporary design of small-molecule kinase modulators: orthosteric, allosteric and induced-proximity strategies
Data & publication
Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion
Data & publication
Roginolisib stabilizes inactive PI3Kδ to deliver specific target blockade with reduced immune toxicity
Data & publication
A renaissance in targeting the PI3K/AKT/mTOR pathway
Data & publication
IOA-244, a novel p110δ PI3K inhibitor, blocks breast tumour progression on either mono- or combined-therapy
Data & publication
The PULMO-01 phase I/IIa Study of Roginolisib in combination with dostarlimab, with or without docetaxel, in patients with advanced non-squamous NSCLC who have progressed on standard of care therapy
Looking for media
resources?